Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
Academy of Medical Sciences & Peking Union Medical College, Beijing/China
Background: There is no optimal therapy established for those who have
progressed with the Epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKI). And some preclinical study indicated that the addition of S-1
to EGFR-TKIs might overcome EGFR-TKI resistance. This study was conducted
to investigate the efficacy and safety of the combination therapy of S-1 and
EGFR-TKIs for patients failed the previous EGFR-TKI treatments. Methods: All
patients who received the combination therapy of S-1 and EGFR-TKIs beyond
progressive disease with EGFR-TKI monotherapy in the Cancer Hospital, the
Chinese Academy of Medical Sciences between 2013 and 2016 with complete
records were enrolled in this study. The primary endpoint was progressionfree
survival (PFS), while the disese control rate and safty were secondary
endpoints. Multivariate analysis for survival was conducted including age,
gender, initiation of EGFR-TKI, the choice of EGFR-TKI, the best efficacy
while using EGFR monotherapy and the choice of S-1 and EGFR-TKI. Results:
A total of 43 non-small-lung cancer (NSCLC) patients who met the inclusion
criteria were enrolled in this study. The median PFS for all patients was 5.47
months (95% confidence interval [CI] 3.444-7.489). The disease control rate
is 67.4%(29/43). There was no grade 4 toxicity and no grade 3 hematologic
toxicity in this study. One patient has grade 3 elevated total serum bilirubin.
Cox analysis showed that the combination treatment of S-1 and erlotinib was
associated with decreased PFS comparing the gefitinib (hazards ratio[HR]
8.401, 95% CI 2.781-25.379, p